HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.

Yanjun HouHiroaki NittaLai WeiPeter M BanksBryce PortierAnil V ParwaniZaibo Li

Published in: Breast cancer research and treatment (2017)

HER2 ITH analyses conducted with GPA method revealed that HER2 ITH is an independent factor predicting incomplete response to anti-HER2 neoadjuvant chemotherapy.

Keyphrases

neoadjuvant chemotherapy
locally advanced
lymph node
sentinel lymph node
single cell
rectal cancer
radiation therapy